Licensing Opportunity: ImmunoFolate™ IP Now Available
Rapid Defense is seeking qualified partners to commercialize our patent-pending ImmunoFolate™ nutraceutical formulation.
About Us
About Rapid Defense
At Rapid Defense, we believe the human body can heal itself, mainly when the immune system works properly. That’s why we’re dedicated to developing therapies and wellness supplements that work with the body, not against it.
We focus on folate and pterin-based immunotherapies, an advanced approach that helps retrain and restore immune function in patients facing severe health challenges.
Whether it’s cancer, sepsis, pneumonia, trauma, or ARDS, our treatments are designed to support the body’s natural defenses and improve its response to illness.
We combine medical science with deep care for patient outcomes. With ImmunoFolate and ImmunoPterin, we aim to provide solutions that fight disease and strengthen the body’s healing abilities safely, effectively, and compassionately.
We are dedicated to transforming the treatment of immune-related diseases through targeted immunotherapies.
ImmunoFolate and ImmunoPterin therapies are rooted in immunological science and designed to support immune reprogramming in oncology and critical care settings.
We specialize in addressing immune dysfunction at its root, aiming to improve survival and recovery in life-threatening conditions like NSCLC, sepsis, and ARDS.
Our Immunotherapies
ImmunoFolate
A next-generation, folate-based immunotherapy that reprograms immune cell behavior in patients with non-small cell lung cancer (NSCLC).
ImmunoFolate enhances immune system function, reduces immunosuppression within the tumor microenvironment, and improves treatment outcomes when used alongside conventional therapies.
Key Hypothesized Benefits:
● Targets folate receptor pathways
● Enhances antigen presentation and T-cell activation
● Reduces tumor-induced immune evasion
ImmunoPterin
ImmunoPterin addresses systemic inflammation and immune dysregulation in acute care scenarios such as ARDS, sepsis, pneumonia, and trauma.
This immunotherapy works by modulating cytokine release, supporting immune balance, and reducing the risk of organ damage.
Key Hypothesized Benefits:
● Supports immune homeostasis
● Helps regulate cytokine storms
● Complements critical care protocols
The Conditions We Target
Rapid Defense's immunotherapies are designed for conditions where immune dysfunction drives disease progression. They include;
- Non-Small Cell Lung Cancer (NSCLC): It is a leading cause of cancer mortality worldwide. Our ImmunoFolate supports immune targeting and tumor responses.
- Acute Respiratory Distress Syndrome (ARDS): This is a common condition, and most cases are in the intensive care unit. ImmunoPtrenine seeks to control systemic inflammation and lung injury.
- Sepsis: This is a life-threatening condition which may cause a patient's immune system to overreact. Our innovative therapies aim to support the immune modulation and prevent overreaction.
- Pneumonia: It leads to a severe lung infection that can progress to ARDS if not addressed early. Our ImmunoFolate aids in immune response regulation.
- Severe Trauma: Immune Dysfunction from uncontrolled trauma may lead to a secondary complication, which our therapies seek to mitigate.
Who We Serve
We are committed to supporting everyone involved in the treatment journey — from the healthcare professionals delivering care to the patients and caregivers living it every day. Our goal is to provide clear, reliable, and practical information tailored to each group’s needs.
Healthcare Professionals
We equip medical experts with the resources they need to make informed treatment decisions and provide the best possible patient care. Our offerings include:
- Mechanism of Action (MOA) Diagrams – Visual explanations that clearly show how each therapy works within the body, making it easier to understand and communicate treatment pathways.
- Prescribing Guidelines & Dosage Forms – Comprehensive instructions and format options to ensure accurate dosing and safe administration.
- Clinical Trial Enrollment Updates – Timely information on ongoing and upcoming trials, including eligibility criteria and enrollment procedures.
- Scientific Dossiers & Safety Profiles – In-depth, evidence-based documentation outlining efficacy, safety data, and research findings to support clinical decision-making.
Patients & Caregivers
We believe knowledge empowers patients and their families to face treatment with confidence. Our patient and caregiver resources are designed to be clear, compassionate, and easy to understand:
- What to Expect During Treatment – Step-by-step guidance on the treatment process, from the first appointment to follow-up care, so there are no surprises along the way.
- Common Questions and Answers – A straightforward FAQ section that addresses everyday concerns about side effects, treatment schedules, lifestyle adjustments, and more.
- Educational Support Resources – Access to brochures, videos, and online tools that explain medical terms, provide self-care tips, and connect patients to additional support networks.
By serving both medical professionals and the people they care for, we aim to create a healthcare experience built on trust, clarity, and partnership.
Our Clinical Trial Initiative
Help Us Launch the First-in Human Study
We are preparing a phase 1/2 clinical trial of Immunofolate for patients with ARDS, non-small cell lung cancer, and metastatic colorectal cancer.
With our trial protocol complete, we are now pursuing FDA IND clearance while raising $10 million in seed funding to advance ImmunoFolate™ into clinical development.
Our Objectives
- Establish safety, tolerability, and optimal dosing
- Measure effects on tumor immune infiltration
- Evaluate progression-free survival
Pioneered by Visionary Scientist Phillip Moheno, Ph.D.
Our Story
Rapid Defense Inc. was founded by Phillip Moheno, Ph.D., a leader in immunotherapy with a passion for developing groundbreaking treatments that harness the body’s natural defenses. With decades of research expertise, Dr. Moheno envisioned a company that will deliver therapies that are both innovative and accessible.